Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24823115 | 0.76 | ACE (0.61) | ACE | |
| SCHEMBL31312437 | 0.74 | ACE (0.34) | ACE | |
| SCHEMBL4461003 | 0.70 | ACE (0.59) | ACE | |
| SCHEMBL4454388 | 0.70 | ACE (0.59) | ACE | |
| SCHEMBL2229670 | 0.70 | ACE (0.59) | ACE | |
| SCHEMBL31510820 | 0.70 | — | — | |
| SCHEMBL3390437 | 0.69 | POLB (0.34) | ACE | |
| SCHEMBL8321174 | 0.69 | — | — | |
| SCHEMBL24820366 | 0.69 | — | — | |
| SCHEMBL1075993 | 0.67 | ACE (0.43) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118027068-A | Compound containing bridged ring and application thereof | 上海艾力斯医药科技股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117430619-A | Pyrazolopyridine compound and preparation method and application thereof | 上海艾力斯医药科技股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-116731044-A | Pyrimidine-containing polycyclic biological inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20090042854-A1 | Hexahydro-3H-Pyrrolizin-3-Ones Useful as Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042854-A1 | Hexahydro-3H-Pyrrolizin-3-Ones Useful as Tachykinin Receptor Antagonists | TACR1, PROKR1, TACR2 | ACE 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.